tiprankstipranks
Cardiol Therapeutics (TSE:CRDL)
TSX:CRDL
Canadian Market
CRDL
Cardiol Therapeutics
RESEARCH TOOLSreports
Want to see TSE:CRDL full AI Analyst Report?

Cardiol Therapeutics (CRDL) Stock Forecast & Price Target

223 Followers
See the Price Targets and Ratings of:

CRDL Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Cardiol
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CRDL Stock 12 Month Forecast

Average Price Target

C$11.74
▲(469.76% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Cardiol Therapeutics in the last 3 months. The average price target is C$11.74 with a high forecast of C$12.43 and a low forecast of C$11.05. The average price target represents a 469.76% change from the last price of C$2.06.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"C$0","13":"C$13","3.25":"C$3.25","6.5":"C$6.5","9.75":"C$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12.42738612,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$12.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.73697578,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$11.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.04656544,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$11.05</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.84,2.654414316923077,3.4688286338461536,4.283242950769231,5.097657267692307,5.912071584615385,6.726485901538461,7.5409002184615375,8.355314535384615,9.169728852307692,9.98414316923077,10.798557486153845,11.612971803076922,{"y":12.42738612,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.84,2.6013058292307694,3.362611658461539,4.1239174876923075,4.885223316923077,5.6465291461538465,6.407834975384615,7.169140804615385,7.930446633846154,8.691752463076924,9.453058292307693,10.214364121538463,10.97566995076923,{"y":11.73697578,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.84,2.5481973415384616,3.2563946830769233,3.964592024615385,4.672789366153847,5.380986707692308,6.089184049230769,6.797381390769231,7.505578732307693,8.213776073846155,8.921973415384617,9.630170756923079,10.338368098461538,{"y":11.04656544,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.695,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.85,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.54,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetC$12.43Average Price TargetC$11.74Lowest Price TargetC$11.05
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on TSE:CRDL
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
C$12.43
Buy
503.27%
Upside
Reiterated
05/26/26
H.C. Wainwright Keeps Their Buy Rating on Cardiol Therapeutics (CRDL)
Canaccord Genuity Analyst forecast on TSE:CRDL
Edward Nash
Canaccord Genuity
Canaccord Genuity
C$11.05
Buy
436.24%
Upside
Reiterated
05/19/26
Analysts Are Bullish on Top Healthcare Stocks: Pharvaris (PHVS), Cardiol Therapeutics (CRDL)
Brookline Capital Markets Analyst forecast on TSE:CRDL
Tyler Bussian
Brookline Capital Markets
Brookline Capital Markets
C$8.28
Buy
302.18%
Upside
Initiated
09/17/25
Cardiol Therapeutics (CRDL) Has a New Rating from Brookline Capital Markets
Roth MKM Analyst forecast on TSE:CRDL
Jason Wittes
Roth MKM
Roth MKM
C$13.81
Buy
570.30%
Upside
Reiterated
09/12/25
Roth MKM Keeps Their Buy Rating on Cardiol Therapeutics (CRDL)
Leede Financial Analyst forecast on TSE:CRDL
Douglas Loe
Leede Financial
Leede Financial
C$15.19
Buy
637.33%
Upside
Reiterated
08/08/25
Is Cardiol Therapeutics a buy?Loe noted that final data arrived only slightly later than expected, with enrollment for the 12-week trial concluding in late fiscal Q3/24 and readout originally anticipated in Q2/25.
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on TSE:CRDL
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
C$12.43
Buy
503.27%
Upside
Reiterated
05/26/26
H.C. Wainwright Keeps Their Buy Rating on Cardiol Therapeutics (CRDL)
Canaccord Genuity Analyst forecast on TSE:CRDL
Edward Nash
Canaccord Genuity
Canaccord Genuity
C$11.05
Buy
436.24%
Upside
Reiterated
05/19/26
Analysts Are Bullish on Top Healthcare Stocks: Pharvaris (PHVS), Cardiol Therapeutics (CRDL)
Brookline Capital Markets Analyst forecast on TSE:CRDL
Tyler Bussian
Brookline Capital Markets
Brookline Capital Markets
C$8.28
Buy
302.18%
Upside
Initiated
09/17/25
Cardiol Therapeutics (CRDL) Has a New Rating from Brookline Capital Markets
Roth MKM Analyst forecast on TSE:CRDL
Jason Wittes
Roth MKM
Roth MKM
C$13.81
Buy
570.30%
Upside
Reiterated
09/12/25
Roth MKM Keeps Their Buy Rating on Cardiol Therapeutics (CRDL)
Leede Financial Analyst forecast on TSE:CRDL
Douglas Loe
Leede Financial
Leede Financial
C$15.19
Buy
637.33%
Upside
Reiterated
08/08/25
Is Cardiol Therapeutics a buy?Loe noted that final data arrived only slightly later than expected, with enrollment for the 12-week trial concluding in late fiscal Q3/24 and readout originally anticipated in Q2/25.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cardiol Therapeutics

3 Months
Edward NashCanaccord Genuity
Success Rate
9/20 ratings generated profit
45%
Average Return
+5.41%
Copying Edward Nash's trades and holding each position for 3 Months would result in 45.00% of your transactions generating a profit, with an average return of +5.41% per trade.
1 Year
Brandon FolkesH.C. Wainwright
Success Rate
6/9 ratings generated profit
67%
Average Return
+14.82%
Copying Brandon Folkes's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +14.82% per trade.
2 Years
Brandon FolkesH.C. Wainwright
Success Rate
6/9 ratings generated profit
67%
Average Return
+14.82%
Copying Brandon Folkes's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +14.82% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRDL Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
4
3
1
4
7
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
4
3
1
4
7
In the current month, CRDL has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CRDL average Analyst price target in the past 3 months is 11.74.
Each month's total comprises the sum of three months' worth of ratings.

CRDL Financial Forecast

CRDL Earnings Forecast

Next quarter’s earnings estimate for CRDL is -C$0.10 with a range of -C$0.12 to -C$0.08. The previous quarter’s EPS was ―. CRDL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CRDL has Performed in-line its overall industry.
Next quarter’s earnings estimate for CRDL is -C$0.10 with a range of -C$0.12 to -C$0.08. The previous quarter’s EPS was ―. CRDL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CRDL has Performed in-line its overall industry.

CRDL Sales Forecast

Next quarter’s sales forecast for CRDL is C$0.00 with a range of C$0.00 to C$0.00. The previous quarter’s sales results were ―. CRDL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CRDL has Performed in-line its overall industry.
Next quarter’s sales forecast for CRDL is C$0.00 with a range of C$0.00 to C$0.00. The previous quarter’s sales results were ―. CRDL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CRDL has Performed in-line its overall industry.

CRDL Stock Forecast FAQ

What is TSE:CRDL’s average 12-month price target, according to analysts?
Based on analyst ratings, Cardiol Therapeutics’s 12-month average price target is 11.74.
    What is TSE:CRDL’s upside potential, based on the analysts’ average price target?
    Cardiol Therapeutics has 469.76% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TSE:CRDL a Buy, Sell or Hold?
          Cardiol Therapeutics has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Cardiol Therapeutics’s price target?
            The average price target for Cardiol Therapeutics is 11.74. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is C$12.43 ,the lowest forecast is C$11.05. The average price target represents 469.76% Increase from the current price of C$2.06.
              What do analysts say about Cardiol Therapeutics?
              Cardiol Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of TSE:CRDL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.